OSE Immunotherapeutics SA (FR:OSE)
:OSE
Top Page
OSE Immunotherapeutics SA
(OSE)
Select Model
Select Model
Rating:49Neutral
Price Target:
€4.50
▼(-9.64% Downside)
Action:ReiteratedDate:11/07/25
The overall stock score for OSE Immunotherapeutics SA is primarily influenced by its financial performance, which shows improvements in profitability and operational efficiency. However, technical analysis indicates bearish momentum, and valuation metrics are weak due to a negative P/E ratio and lack of dividend yield. These factors collectively suggest caution for potential investors.
Positive Factors
Profitability Improvements
The significant improvement in net profit margin indicates enhanced profitability, suggesting that the company is managing costs effectively and improving its bottom line, which is crucial for long-term sustainability.
Negative Factors
Declining Revenue
The negative revenue growth rate is a concern as it indicates declining sales, which could impact the company's ability to sustain profitability and growth in the long term.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Improvements
The significant improvement in net profit margin indicates enhanced profitability, suggesting that the company is managing costs effectively and improving its bottom line, which is crucial for long-term sustainability.
Read all positive factors
OSE Immunotherapeutics SA (OSE) vs. iShares MSCI France ETF (EWQ)
Market Cap
€67.65M
Dividend YieldN/A
Average Volume (3M)154.47K
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue Growth-96.92%
EPS Growth-175.84%
CountryFR
Employees64
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.68
Shares Outstanding22,463,263
10 Day Avg. Volume172,695
30 Day Avg. Volume154,469
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.45
Price to Sales (P/S)2.24
P/FCF Ratio3.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.04
Revenue Forecast (FY)€10.63M
OSE Immunotherapeutics SA Business Overview & Revenue Model
Company Description
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatmen...
How the Company Makes Money
OSE Immunotherapeutics generates revenue primarily through a combination of product development partnerships, licensing agreements, and potential future sales of its therapeutic candidates. The company collaborates with pharmaceutical companies an...
OSE Immunotherapeutics SA Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
60
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.15M | 69.88M | 2.23M | 18.30M | 26.31M | 10.42M |
| Gross Profit | 862.00K | 69.88M | 2.23M | 18.30M | 26.31M | 10.42M |
| EBITDA | -34.29M | 41.20M | -17.50M | -13.11M | -13.72M | -18.24M |
| Net Income | -34.84M | 37.45M | -23.00M | -17.76M | -16.85M | -16.55M |
Balance Sheet | ||||||
| Total Assets | 104.18M | 123.96M | 82.05M | 91.67M | 101.52M | 96.85M |
| Cash, Cash Equivalents and Short-Term Investments | 41.59M | 16.75M | 18.67M | 25.62M | 33.58M | 29.37M |
| Total Debt | 38.66M | 46.13M | 45.80M | 44.79M | 37.13M | 19.51M |
| Total Liabilities | 53.58M | 60.15M | 59.08M | 59.12M | 53.99M | 35.61M |
| Stockholders Equity | 50.60M | 63.81M | 22.82M | 32.55M | 47.89M | 61.24M |
Cash Flow | ||||||
| Free Cash Flow | -36.24M | 48.36M | -20.00M | -18.53M | -10.39M | -19.76M |
| Operating Cash Flow | -36.17M | 48.44M | -19.76M | -18.25M | -9.92M | -19.55M |
| Investing Cash Flow | 38.38M | -46.91M | -507.00K | 26.00K | -827.00K | -504.00K |
| Financing Cash Flow | -2.19M | -3.46M | 13.32M | 10.27M | 14.96M | 23.58M |
OSE Immunotherapeutics SA Technical Analysis
Negative
4.98
Price Trends
4.28
Negative
4.74
Negative
5.33
Negative
Market Momentum
-0.30
Positive
21.98
Positive
16.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:OSE, the sentiment is Negative. The current price of 4.98 is above the 20-day moving average (MA) of 3.81, above the 50-day MA of 4.28, and below the 200-day MA of 5.33, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 21.98 is Positive, neither overbought nor oversold. The STOCH value of 16.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:OSE.
OSE Immunotherapeutics SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | €7.51B | -24.91 | ― | ― | ― | 18.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €201.05M | -3.69 | -634.16% | ― | 111.76% | -22.45% | |
49 Neutral | €67.65M | -1.87 | -52.76% | ― | -96.92% | -175.84% | |
48 Neutral | €121.60M | -1.20 | ― | ― | 52.55% | -5.97% | |
44 Neutral | €101.63M | -2.91 | -658.91% | ― | -75.86% | -30.54% | |
44 Neutral | €206.13M | -7.03 | -30.75% | ― | 150.80% | 67.81% |
* Healthcare Sector Average
FR:OSE
OSE Immunotherapeutics SA
3.02
-3.13
-50.96%
FR:IPH
Innate Pharma SA
1.08
-0.79
-42.19%
FR:ABVX
Abivax SA
94.80
88.56
1419.23%
FR:TNG
Transgene
0.73
0.06
9.39%
FR:ALCLS
Cellectis SA
2.85
1.59
126.19%
FR:MAAT
MaaT Pharma
6.46
0.14
2.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.